{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:43:29Z","timestamp":1790790209941,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.amjcard.2022.10.014","type":"journal-article","created":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T21:22:01Z","timestamp":1668028921000},"page":"S23-S34","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"S1","title":["Overview of Current and Emerging Therapies for Amyloid Transthyretin Cardiomyopathy"],"prefix":"10.1016","volume":"185","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5400-5008","authenticated-orcid":false,"given":"Mathew S.","family":"Maurer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2022.10.014_bib0001","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1126\/science.1062245","article-title":"Trans-suppression of misfolding in an amyloid disease","volume":"293","author":"Hammarstr\u00f6m","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.amjcard.2022.10.014_bib0002","doi-asserted-by":"crossref","first-page":"14943","DOI":"10.1073\/pnas.261419998","article-title":"The V122I cardiomyopathy variant of transthyretin increases the velocity of rate-limiting tetramer dissociation, resulting in accelerated amyloidosis","volume":"98","author":"Jiang","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.amjcard.2022.10.014_bib0003","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0065-3233(08)60321-6","article-title":"Transthyretin quaternary and tertiary structural changes facilitate misassembly into amyloid","volume":"50","author":"Kelly","year":"1997","journal-title":"Adv Protein Chem"},{"key":"10.1016\/j.amjcard.2022.10.014_bib0004","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1073\/pnas.87.7.2843","article-title":"Fibril in senile systemic amyloidosis is derived from normal transthyretin","volume":"87","author":"Westermark","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.amjcard.2022.10.014_bib0005","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/0022-2836(78)90368-6","article-title":"Structure of prealbumin: secondary, tertiary and quaternary interactions determined by Fourier refinement at 1.8 A","volume":"121","author":"Blake","year":"1978","journal-title":"J Mol Biol"},{"key":"10.1016\/j.amjcard.2022.10.014_bib0006","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1126\/science.7754382","article-title":"Structure of a complex of two plasma proteins: transthyretin and retinol-binding protein","volume":"268","author":"Monaco","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.amjcard.2022.10.014_bib0007","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC State-of-the-Art Review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2022.10.014_bib0008","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2022.10.014_bib0009","unstructured":"Attralus. Attralus presents positive new data at 2021 American Society of Hematology Annual Meeting. Available at:https:\/\/attralus.com\/wp-content\/uploads\/2022\/01\/61b740cfaefddf69719bc441_Attralus-ASH-Data-Press-Release-13Dec2021.pdf. Accessed on April 11, 2022."},{"key":"10.1016\/j.amjcard.2022.10.014_bib0010","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2217\/nmt-2018-0037","article-title":"Inotersen (transthyretin-specific antisense oligonucleotide) for treatment of transthyretin amyloidosis","volume":"9","author":"Benson","year":"2019","journal-title":"Neurodegener Dis Manag"},{"key":"10.1016\/j.amjcard.2022.10.014_bib0011","unstructured":"BridgeBio. BridgeBio Pharma reports month 12 topline results from phase 3 ATTRibute-CM study. Available at:https:\/\/bridgebio.com\/news\/bridgebio-pharma-reports-month-12-topline-results-from-phase-3-attribute-cm-study. Accessed on April 11, 2022."},{"key":"10.1016\/j.amjcard.2022.10.014_bib0012","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3390\/ph12020078","article-title":"Tegsedi (Inotersen): an antisense oligonucleotide approved for the treatment of adult patients with hereditary transthyretin amyloidosis","volume":"12","author":"Gales","year":"2019","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.amjcard.2022.10.014_bib0013","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ejhf.2140","article-title":"Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases","volume":"23","author":"Garcia-Pavia","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.amjcard.2022.10.014_bib0014","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2022.10.014_bib0015","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/cpt.1974","article-title":"Single-dose pharmacokinetics and pharmacodynamics of transthyretin targeting N-acetylgalactosamine-small interfering ribonucleic acid conjugate, vutrisiran, in healthy subjects","volume":"109","author":"Habtemariam","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.amjcard.2022.10.014_bib0016","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jacc.2019.03.012","article-title":"Transthyretin stabilization by AG10 in symptomatic transthyretin amyloid cardiomyopathy","volume":"74","author":"Judge","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2022.10.014_bib0017","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1161\/CIR.0000000000000792","article-title":"American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology. Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association","volume":"142","author":"Kittleson","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2022.10.014_bib0018","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.cardfail.2019.11.024","article-title":"Stabilization of cardiac function with diflunisal in transthyretin (ATTR) cardiac amyloidosis","volume":"26","author":"Lohrmann","year":"2020","journal-title":"J Card Fail"},{"key":"10.1016\/j.amjcard.2022.10.014_bib0019","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"ATTR-ACT Study Investigators. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2022.10.014_bib0020","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1038\/s41467-021-23274-x","article-title":"A human antibody selective for transthyretin amyloid removes cardiac amyloid through phagocytic immune cells","volume":"12","author":"Michalon","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.amjcard.2022.10.014_bib0021","unstructured":"Neurimmune. Neurimmune announces the initiation of a phase 1 study of NI006 for the treatment of ATTR cardiomyopathy. Available at:https:\/\/www.neurimmune.com\/news\/neurimmune-announces-the-initiation-of-a-phase-1-study-of-ni006-for-the-treatment-of-attr-cardiomyopathy. Accessed on April 11, 2022."},{"key":"10.1016\/j.amjcard.2022.10.014_bib0022","unstructured":"Prothena. Prothena reports positive 9 month results from phase 1 long-term extension study of PRX004, the first investigational anti-amyloid immunotherapy for the treatment of ATTR amyloidosis. Available at:https:\/\/s29.q4cdn.com\/936209790\/files\/doc_news\/archive\/0a6f3106-ff2d-4170-9101-929def1dde04.pdf. Accessed on April 11, 2022."},{"key":"10.1016\/j.amjcard.2022.10.014_bib0023","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004769","article-title":"TTR (transthyretin) stabilizers are associated with improved survival in patients with TTR cardiac amyloidosis","volume":"11","author":"Rosenblum","year":"2018","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.amjcard.2022.10.014_bib0024","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1080\/13506120600960882","article-title":"Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis","volume":"13","author":"Sekijima","year":"2006","journal-title":"Amyloid"},{"key":"10.1016\/j.amjcard.2022.10.014_bib0025","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","article-title":"Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis","volume":"139","author":"Solomon","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2022.10.014_bib0026","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s40120-020-00208-1","article-title":"A review of patisiran (Onpattro\u00ae) for the treatment of polyneuropathy in people with hereditary transthyretin amyloidosis","volume":"9","author":"Urits","year":"2020","journal-title":"Neurol Ther"},{"key":"10.1016\/j.amjcard.2022.10.014_bib0027","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/ehf2.13154","article-title":"Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data","volume":"8","author":"Viney","year":"2021","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.amjcard.2022.10.014_bib0028","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1001\/jama.2013.283815","article-title":"Diflunisal Trial Consortium. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial","volume":"310","author":"Berk","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2022.10.014_bib0029","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1161\/CIRCULATIONAHA.119.045093","article-title":"Cost-effectiveness of tafamidis therapy for transthyretin amyloid cardiomyopathy","volume":"141","author":"Kazi","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2022.10.014_bib0030","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/13506129.2018.1519507","article-title":"Diflunisal tolerability in transthyretin cardiac amyloidosis: a single center's experience","volume":"25","author":"Ikram","year":"2018","journal-title":"Amyloid"},{"key":"10.1016\/j.amjcard.2022.10.014_bib0031","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1016\/j.jacc.2019.03.484","article-title":"Statistical appraisal of 6 recent clinical trials in cardiology: JACC State-of-the-Art Review","volume":"73","author":"Pocock","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2022.10.014_bib0032","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1161\/CIRCULATIONAHA.119.041015","article-title":"The truth is unfolding about transthyretin cardiac amyloidosis","volume":"140","author":"Grodin","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2022.10.014_bib0033","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1080\/13506129.2021.1904390","article-title":"Factors associated with changes in serum transthyretin after treatment with tafamidis and outcomes in transthyretin cardiac amyloidosis","volume":"28","author":"Saith","year":"2021","journal-title":"Amyloid"},{"key":"10.1016\/j.amjcard.2022.10.014_bib0034","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.022859","article-title":"Lack of association between neurohormonal blockade and survival in transthyretin cardiac amyloidosis","volume":"10","author":"Cheng","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.amjcard.2022.10.014_bib0035","unstructured":"Alnylam Pharmaceuticals. Alnylam completes enrollment in Apollo-B phase 3 study of patisiran in transthyretin mediated (ATTR) amyloidosis patients with cardiomyopathy. Available at: https:\/\/investors.alnylam.com\/press-release?id=25926. Accessed on April 11, 2022."},{"key":"10.1016\/j.amjcard.2022.10.014_bib0036","unstructured":"Maurer MS, Fontana M, Berk JL, Gustafsson F, Simoes M, Grogan M, Fernandes F, Gottlieb RL, Kubanek M, Poulsen S, Damy T, Diemberger I, Tahara N, Yu W-C, Tang WHW, Obici L, Gonz\u00e1lez-Duarte A, Sekijima Y, White MT, Yueneva E, Jay PY, Vest J, Gillmore JD. Primary results from APOLLO-B, a phase 3 study of patisiran in patients with transthyretin-mediated amyloidosis with cardiomyopathy. Available at: https:\/\/capella.alnylam.com\/wp-content\/uploads\/2022\/09\/Maurer-et-al-ISA-2022.pdf.39. Accessed on September 21, 2022."},{"key":"10.1016\/j.amjcard.2022.10.014_bib0037","unstructured":"Alnylam Pharmaceuticals. Alnylam presents positive results from HELIOS-A phase 3 study of investigational vutrisiran. Available at: https:\/\/investors.alnylam.com\/press-release?id=25656. Accessed on April 11, 2022."},{"key":"10.1016\/j.amjcard.2022.10.014_bib0038","unstructured":"Alnylam Pharmaceuticals. Alnylam presents positive 18-month results from HELIOS-A phase 3 study of investigational vutrisiran in patients with hATTR amyloidosis with polyneuropathy. Available at: https:\/\/investors.alnylam.com\/press-release?id=26396. Accessed on April 11, 2022."},{"key":"10.1016\/j.amjcard.2022.10.014_bib0039","unstructured":"Intellia Therapeutics. Intellia and Regeneron announce updated phase 1 data demonstrating a single dose of NTLA-2001, an investigational CRISPR therapy for transthyretin (ATTR) amyloidosis, resulted in rapid, deep and sustained reduction in disease-causing protein. Available at: https:\/\/ir.intelliatx.com\/news-releases\/news-release-details\/intellia-and-regeneron-announce-updated-phase-1-data. Accessed on April 11, 2022."}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914922010773?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914922010773?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:07:16Z","timestamp":1762078036000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914922010773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":39,"alternative-id":["S0002914922010773"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2022.10.014","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overview of Current and Emerging Therapies for Amyloid Transthyretin Cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2022.10.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}